1 | Preoperative combined modality therapy for pancreatic cancer. (Rich TA, Evans DB) World J Surg 1995;19(2):264-9 31 Citations |
1 | Erratum: Combined modality therapy for cutaneous T-cell lymphoma (Journal of the American Academy of Dermatology (1996) 34 (1022-1029)) (Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock R) Journal of the American Academy of Dermatology 1996;35(4):587 1 Citation |
1 | Combined modality therapy for cutaneous T-cell lymphoma. (Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock R) J Am Acad Dermatol 1996 Jun;34(6):1022-9 79 Citations |
1 | Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. (Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R) J Am Acad Dermatol 2003 Jul;49(1):35-49 60 Citations |
2 | Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). (Firat S, Pleister A, Byhardt RW, Gore E) Am J Clin Oncol 2006 Jun;29(3):252-7 46 Citations |
1 | Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. (Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA) Clin Colorectal Cancer 2008 Sep;7(5):338-42 |